<clinical_study>
<study_id>
<org_name>
  Novo_Nordisk
</org_name>
<org_full_name>
  Novo Nordisk
</org_full_name>
<org_study_id>
  NN304-1613
</org_study_id>
<nct_id>
  NCT00184600
</nct_id>
</study_id>
<brief_title>
<textblock>
  Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
</textblock>
</brief_title>
<official_title>
<textblock>
  3 Year Efficacy and Safety Comparison of Adding Insulin Detemir, Biphasic Insulin Aspart 30 or Insulin Aspart to Oral Antidiabetic Drug Treatment in Type 2 Diabetes.
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Novo Nordisk
</agency>
</lead_sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  United Kingdom: Medicines and Healthcare Products Regulatory Agency
</regulatory_authority>
<regulatory_authority>
  Ireland: Irish Medicines Board
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  This trial is conducted in Europe.
 
  The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD treatment in type 2 diabetes and to verify the safety of use ( number and severity of episodes of hypoglycaemia, body weight and side effects).
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
 No longer recruiting 
</status>
<date>
2006-10 
</date>
</status_block>
<start_date>
<date>
  2004-11
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 4
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<primary_outcome>
  Proportion of subjects who achieve HbA1c &#8804; 6.5% without hypoglycaemia in the last 4 weeks of year 1/year 3, Efficacy and durability of the insulin regimens over a 12-36months following a treatment algorithm
</primary_outcome>
<secondary_outcome>
  Body weight
</secondary_outcome>
<secondary_outcome>
  Quality of Life
</secondary_outcome>
<secondary_outcome>
  Blood glucose
</secondary_outcome>
<secondary_outcome>
  Hypoglycaemia
</secondary_outcome>
<secondary_outcome>
  Adverse events
</secondary_outcome>
<condition>
  Diabetes Mellitus, Type 2
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Insulin detemir
</primary_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Insulin aspart
</primary_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Biphasic insulin aspart 30
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - Type 2 Diabetes
    - Insulin naive
    - On OAD treatment
    - BMI &#8804; 40.0 kg/m2
    - HbA1c7.0%-10% (both inclusive)
 
  Exclusion Criteria:
    - Proliferative retinopathy
    - Recurrent major hypoglycaemia
    - Cardial problems
    - Uncontrolled hypertension
    - Impaired hepatic or renal function
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<patients>
</patients>
<expected_enrollment>
  700
</expected_enrollment>
<gender>
  Both
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  N/A
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Eric Teo, BS
</name>
<affiliation>
<agency>
  Novo Nordisk Limited
</agency>
</affiliation>
</investigator>
<contact>
<name>
  Public Access to Clinical Trials - Novo Nordisk.
</name>
<phone>
  Please contact NN via email:
</phone>
<phone_ext>
</phone_ext>
<email>
  clinicaltrials@novonordisk.com
</email>
</contact>
<location>
<facility>
<name>
  Metabolic Research Unit, Hospital 5, St James&#8217;s Hospital
</name>
<address>
<city>
  Dublin
</city>
<state>
</state>
<zip>
</zip>
<country>
  Ireland
</country>
</address>
</facility>
<status>
 No longer recruiting 
</status>
<contact>
<name>
</name>
<phone>
  Contact NN via URL link below.
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Oxford Centre for Diabetes, Endocrinology &amp; Metabolism
</name>
<address>
<city>
  Oxford
</city>
<state>
</state>
<zip>
</zip>
<country>
  United Kingdom
</country>
</address>
</facility>
<status>
 No longer recruiting 
</status>
<contact>
<name>
</name>
<phone>
  Contact NN via URL link below.
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<initial_release_date>
  2005-09-13
</initial_release_date>
<last_release_date>
2006-10-11 
</last_release_date>
</clinical_study>
